US Patent 12076321 (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
Patent 12076321 was granted and assigned to Centrexion Therapeutics on September, 2024 by the United States Patent and Trademark Office.
Is a
Current Assignee
Date Filed
October 13, 2021
0
Date of Patent
September 3, 2024
0
Patent Applicant
Patent Application Number
17500367
0
Patent Citations
•••
Patent Inventor Names
Ulrike Werthmann
0
Markus Ostermeier
0
Patent Jurisdiction
Patent Number
Patent Primary Examiner
Find more entities like US Patent 12076321 (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.